FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peyman Hadji

Research Profile

Concepts & Ideas

Disorders

Chemicals & Drugs

Anatomy

Procedures

Physiology

Geographic Areas

Germany

Co-author Network

Publications

TOP 3
Mathias Kalder; Dana Knöll; Ioannis Kyvernitakis; V Ziller; Olaf Hars; Peyman Hadji
Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
Peyman Hadji; M Bauer; G Haas; J Kyvernitakis; N Schmidt; V Ziller; Karel Kostev
Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis.
Peyman Hadji
The evolution of selective estrogen receptor modulators in osteoporosis therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peyman Hadji (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mathias Kalder; Dana Knöll; Ioannis Kyvernitakis; V Ziller; Olaf Hars; Peyman Hadji
Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
Journal of cancer research and clinical oncology 2013;139(6):915-23.
2013: Peyman Hadji; M Bauer; G Haas; J Kyvernitakis; N Schmidt; V Ziller; Karel Kostev
Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis.
Breast cancer research and treatment 2013;138(1):185-91.
2012: Peyman Hadji
The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Climacteric : the journal of the International Menopause Society 2012;15(6):513-23.
2012: May Ziller; V Ziller; Julia Herwig; Annette Kauka; Karel Kostev; Peyman Hadji
Effects of a low-dose oral estrogen only treatment on bone mineral density and quantitative ultrasonometry in postmenopausal women.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2012;28(12):1002-5.
2012: Peyman Hadji; R Coleman; M Gnant; J Green
The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(11):2782-90.
2012: Peyman Hadji; Matti Aapro; Luis Costa; Michael Gnant
Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations.
Cancer treatment reviews 2012;38(6):815-24.
2012: Peyman Hadji; Jutta Biskup; Jelena Boekhoff; Michael Bonn; May Ziller; Lucio Rovati
Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg.
Contraception 2012;86(4):359-65.
2012: Peyman Hadji; A Lipton; J J Body; A Brufsky; N J Bundred; R E Coleman; M Gnant; T A Guise; M S Aapro
Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?
Cancer treatment reviews 2012;38(6):798-806.
2012: Peyman Hadji; John Krege; M C Lakshmanan; D N Masica; F E McKiernan; Bruce H Mitlak; C P Recknor; L Russo; Kenneth G Saag; S L Silverman; J Alam; R T Burge; J R Zanchetta; John L Stock
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012;23(8):2141-50.
2012: Peyman Hadji; K Articus; M Baier; D Gamerdinger; R Moericke; W Spieler; V Ziller; P H Kann
Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012;23(7):2043-51.
2012: Peyman Hadji; Olaf Hars; Melanie Hartenfels; Klaus Heinrich Baumann; Jannis Kyvernitakis; Mathias Kalder
Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES).
Breast cancer research and treatment 2012;133(3):1089-96.
2012: V Ziller; Jelena Boeckhoff; Karel Kostev; Ioannis Kyvernitakis; Peyman Hadji
Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database.
International journal of clinical pharmacology and therapeutics 2012;50(5):315-22.
2012: Peyman Hadji
Breast cancer: Aromatase inhibitors--bone health assessment is crucial.
Nature reviews. Clinical oncology 2012;9(5):254-5.
2012: Peyman Hadji; Karel Kostev; Detlef Schröder-Bernhardi; V Ziller
Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
International journal of clinical pharmacology and therapeutics 2012;50(4):281-9.
2012: Peyman Hadji; P H Kann; H Loeffler; R Möricke; W Spieler; K Articus; D Gamerdinger; V Ziller
Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012;23(2):625-33.
2011: Peyman Hadji; M S Aapro; J J Body; A Brufsky; N J Bundred; R E Coleman; M Gnant; T Guise; A Lipton
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(12):2546-55.
2011: Robert Coleman; Richard Cook; Luis Costa; Meletios Dimopoulos; Patrick Garnero; Peyman Hadji; Ker-Ai Lee; Pierre Major; Fred Saad; Matthew Smith; Evangelos Terpos; Jean-Jacques Body; Janet Brown; Allan Lipton
Consensus on the utility of bone markers in the malignant bone disease setting.
Critical reviews in oncology/hematology 2011;80(3):411-32.
2011: Peyman Hadji
Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease.
Critical reviews in oncology/hematology 2011;80(2):301-13.
2011: Peyman Hadji; Allan Lipton; Matti Aapro; Michael Gnant; Robert Coleman
Dosing of zoledronic acid throughout the treatment continuum in breast cancer.
Critical reviews in oncology/hematology 2011;79(2):175-88.
2011: Mathias Kalder; C Jäger; B Seker-Pektas; K Dinas; I Kyvernitakis; Peyman Hadji
Breast cancer and bone mineral density: the Marburg Breast Cancer and Osteoporosis Trial (MABOT II).
Climacteric : the journal of the International Menopause Society 2011;14(3):352-61.
2011: Peyman Hadji
Managing bone health with zoledronic acid: a review of randomized clinical study results.
Climacteric : the journal of the International Menopause Society 2011;14(3):321-32.
2011: Peyman Hadji; Lina Asmar; Johanna G H van Nes; Thomas Menschik; Annette Hasenburg; Joachim Kuck; Johan W R Nortier; Cornelis J H van de Velde; Stephen E Jones; May Ziller
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.
Journal of cancer research and clinical oncology 2011;137(6):1015-25.
2011: V Ziller; K Wetzel; I Kyvernitakis; B Seker-Pektas; Peyman Hadji
Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene.
Climacteric : the journal of the International Menopause Society 2011;14(2):228-35.
2010: Lars Hellmeyer; Jelena Boekhoff; Peyman Hadji
Treatment with teriparatide in a patient with pregnancy-associated osteoporosis.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2010;26(10):725-8.
2010: Peyman Hadji
Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.
Critical reviews in oncology/hematology 2010;73(2):156-66.
2009: Peyman Hadji; May Ziller; Carolin Maskow; Ute-Susann Albert; Matthias Kalder
The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer.
European journal of cancer (Oxford, England : 1990) 2009;45(18):3205-12.
2009: Peyman Hadji; M Ziller; D G Kieback; W Dornoff; H W Tessen; T Menschik; J Kuck; F Melchert; A Hasenburg
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(7):1203-9.
2009: Peyman Hadji; M Ziller; D G Kieback; T Menschik; Mathias Kalder; J Kuck; A Hasenburg
The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Breast (Edinburgh, Scotland) 2009;18(3):159-64.
2009: Ana Munoz; Thomas Nickelsen; Fernando Marin; Clare Barker; Peyman Hadji; Jordi Farrerons; Maurice Audran; Steven Boonen; Kim Brixen; Jose Melo Gomes; Barbara Obermayer-Pietsch; Avraam Avramidis; Gunnar Sigurdsson; Claus Glüer
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2009;24(4):726-36.
2009: V Ziller; Mathias Kalder; U-S Albert; W Holzhauer; M Ziller; Uwe Wagner; Peyman Hadji
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(3):431-6.
2009: Peyman Hadji
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
Critical reviews in oncology/hematology 2009;69(1):73-82.
2008: Robert E Coleman; Theresa A Guise; Allan Lipton; David G Roodman; James R Berenson; Jean-Jacques Body; Brendan F Boyce; Laura M Calvi; Peyman Hadji; Eugene McCloskey; Fred Saad; Matthew R Smith; Larry J Suva; Russell S Taichman; Robert L Vessella; Katherine N Weilbaecher
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6387-95.
2008: Barbara Obermayer-Pietsch; Fernando Marin; Eugene V McCloskey; Peyman Hadji; Jordi Farrerons; Steven Boonen; Maurice Audran; Clare Barker; Athanasios D Anastasilakis; William D Fraser; Thomas Nickelsen
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2008;23(10):1591-600.
2008: Peyman Hadji; J-J Body; M S Aapro; A Brufsky; R E Coleman; T Guise; A Lipton; M Tubiana-Hulin
Practical guidance for the management of aromatase inhibitor-associated bone loss.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(8):1407-16.
2008: Adam Brufsky; Nigel Bundred; Robert Coleman; Rosemary Lambert-Falls; Raul Mena; Peyman Hadji; Lixian Jin; Nora Schenk; Solveig Ericson; Edith A Perez
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
The oncologist 2008;13(5):503-14.
2008: Peyman Hadji; Helmut Minne; Michael Pfeifer; Pierre Bourgeois; Patrice Fardellone; Angelo Licata; Vipul Devas; Daiva Masanauskaite; Elizabeth Barrett-Connor
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).
Joint, bone, spine : revue du rhumatisme 2008;75(3):303-10.
2008: Georgia Anderer; Lars Hellmeyer; Peyman Hadji
Clinical management of a pregnant patient with type I osteogenesis imperfecta using quantitative ultrasonometry--a case report.
Ultraschall in der Medizin (Stuttgart, Germany : 1980) 2008;29(2):201-4.
2008: Peyman Hadji
Menopausal symptoms and adjuvant therapy-associated adverse events.
Endocrine-related cancer 2008;15(1):73-90.
2008: Steven Boonen; Fernando Marin; Barbara Obermayer-Pietsch; Maria E Simões; Clare Barker; Emmett Glass; Peyman Hadji; George Lyritis; Heide Oertel; Thomas Nickelsen; Eugene V McCloskey
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
The Journal of clinical endocrinology and metabolism 2008;93(3):852-60.
2008: Didier Hans; John A Shepherd; Elliott N Schwartz; David M Reid; Glen M Blake; John N Fordham; Thomas Fuerst; Peyman Hadji; Akira Itabashi; Marc-Antoine Krieg; E Michael Lewiecki
Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2008;11(1):188-206.
2007: Peyman Hadji; Nigel Bundred
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Seminars in oncology 2007;34(6 Suppl 4):S4-10.
2007: P Collins; Giuseppe Rosano; C Casey; C Daly; Marco Gambacciani; Peyman Hadji; R Kaaja; T Mikkola; S Palacios; Richard A Preston; T Simon; J Stevenson; Marco Stramba-Badiale
Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists.
Climacteric : the journal of the International Menopause Society 2007;10(6):508-26.
2007: Peyman Hadji
Reducing the risk of bone loss associated with breast cancer treatment.
Breast (Edinburgh, Scotland) 2007;16 Suppl 3():S10-5.
2007: Peter Collins; Giuseppe Rosano; Catherine Casey; Caroline Daly; Marco Gambacciani; Peyman Hadji; Risto Kaaja; Tomi Mikkola; Santiago Palacios; Richard A Preston; Tabassome Simon; John Stevenson; Marco Stramba-Badiale
[Management of cardiovascular risk in the peri-menopausal woman--a consensus statement of European cardiologists and gynaecologists].
Kardiologia polska 2007;65(11):1331-46; discussion 1347-49.
2007: Peter Collins; Giuseppe Rosano; Catherine Casey; Caroline Daly; Marco Gambacciani; Peyman Hadji; Risto Kaaja; Tomi Mikkola; Santiago Palacios; Richard A Preston; Tabassome Simon; John Stevenson; Marco Stramba-Badiale
Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists.
European heart journal 2007;28(16):2028-40.
2007: Peyman Hadji; May Gottschalk; V Ziller; Mathias Kalder; Christian Jackisch; Uwe Wagner
Bone mass and the risk of breast cancer: the influence of cumulative exposure to oestrogen and reproductive correlates. Results of the Marburg breast cancer and osteoporosis trial (MABOT).
Maturitas 2007;56(3):312-21.
2007: Lars Hellmeyer; Maritta Kühnert; V Ziller; Stephan Schmidt; Peyman Hadji
The use of i. v. bisphosphonate in pregnancy-associated osteoporosis--case study.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2007;115(2):139-42.
2007: Paul E Goss; Peyman Hadji; Milayna Subar; Paula Abreu; Torben Thomsen; Jose Banke-Bochita
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Breast cancer research : BCR 2007;9(4):R52.
2006: Lars Hellmeyer; A Ossendorf; V Ziller; Ismail Tekesin; Stephan Schmidt; Peyman Hadji
Quantitative ultrasonometry of the phalanges during pregnancy: a longitudinal study.
Climacteric : the journal of the International Menopause Society 2006;9(6):446-51.
2006: Lars Hellmeyer; V Ziller; Georgia Anderer; A Ossendorf; Stephan Schmidt; Peyman Hadji
Biochemical markers of bone turnover during pregnancy: a longitudinal study.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2006;114(9):506-10.
2006: Lars Hellmeyer; Georgia Anderer; V Ziller; Uwe Wagner; Stephan Schmidt; Peyman Hadji
[Evaluation of quantitative ultrasonometry of bone in singleton and multiple pregnancies].
Zeitschrift für Geburtshilfe und Neonatologie 2006;210(5):179-83.
2006: Karin Bock; Peyman Hadji; Annette Ramaswamy; Stephan Schmidt; Volker F Duda
Rationale for a diagnostic chain in gestational breast tumor diagnosis.
Archives of gynecology and obstetrics 2006;273(6):337-45.
2005: F Fischer; M Kuhl; U Feek; M Rominger; M L Schipper; Peyman Hadji; U Wagner; Christian Jackisch
Bone metastases in vulvar cancer: a rare metastatic pattern.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(6):1173-6.
2005: Michael Schnabel; G Eser; V Ziller; D Mann; E Mann; Peyman Hadji
[Bone mineral density in postmenopausal women with proximal femoral fractures--comparative study between quantitative ultrasonometry and gold standard DXA].
Zentralblatt für Chirurgie 2005;130(5):469-75.
2005: Karin Bock; Volker F Duda; Peyman Hadji; Annette Ramaswamy; Rüdiger Schulz-Wendtland; Klaus Jochen Klose; Uwe Wagner
Pathologic breast conditions in childhood and adolescence: evaluation by sonographic diagnosis.
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 2005;24(10):1347-54; quiz 1356-7.
2005: Karin Bock; Peyman Hadji; Volker F Duda; Christian Jackisch; Uwe Wagner
[Mammographic breast density and breast cancer risk during HRT].
Zentralblatt für Gynäkologie 2005;127(4):217-21.
2004: Karin Bock; Peyman Hadji; Klaus-Dieter Schulz; Uwe Wagner; Volker F Duda
[Differential diagnosis of Poland-syndrome versus unilateral accentuated thelarche].
Ultraschall in der Medizin (Stuttgart, Germany : 1980) 2004;25(5):377-82.
2004: Henry Burger; David Archer; David Barlow; Martin H Birkhäuser; Joaquim Calaf-Alsina; Marco Gambacciani; Andrea Genazzani; Peyman Hadji; Ole-Erik Iversen; Herbert Kuhl; Rogerio A Lobo; Thierry Maudelonde; Manuel Neves e Castro; Morris Notelovitz; Santiago Palacios; Tomasz Paszkowski; Eitan Peer; Amos Pines; Göran Samsioe; John Stevenson; Sven O Skouby; David W Sturdee; Tobie de Villiers; Malcolm Whitehead; Olavi Ylikorkala
Practical recommendations for hormone replacement therapy in the peri- and postmenopause.
Climacteric : the journal of the International Menopause Society 2004;7(2):210-6.
2004: Marco Gambacciani; Domenico De Aloysio; David Elia; Marius J van der Mooren; Peyman Hadji; Christian Wüster
Quantitative ultrasound (QUS) of bone in the management of postmenopausal women.
Maturitas 2004;47(2):139-49.
2004: Peyman Hadji
[When is hormone therapy useful?].
Pharmazie in unserer Zeit 2004;33(5):372-7.
2003: Peyman Hadji
[Possibilities and limitations of quantitative ultrasonometry in clinical practise].
Deutsche medizinische Wochenschrift (1946) 2003;128(17):951-3.
2003: Peyman Hadji; Karin Bock; M Gotschalk; Olaf Hars; J Backhus; Günter Emons; Klaus-Dieter Schulz
The influence of serum leptin concentration on bone mass assessed by quantitative ultrasonometry in pre and postmenopausal women.
Maturitas 2003;44(2):141-8.
2002: Peyman Hadji; V Ziller; Mathias Kalder; May Gottschalk; Lars Hellmeyer; Olaf Hars; Stephan Schmidt; Klaus-Dieter Schulz
Influence of pregnancy and breast-feeding on quantitative ultrasonometry of bone in postmenopausal women.
Climacteric : the journal of the International Menopause Society 2002;5(3):277-85.
2002: Peyman Hadji; Mathias Kalder; J Backhus; May Gottschalk; Olaf Hars; Klaus-Dieter Schulz
Age-associated changes in bone ultrasonometry of the os calcis.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2002;5(3):297-303.
2001: Karin Bock; Joanna Iwinska-Zelder; Volker F Duda; C Bonwetsch; G Rode; Peyman Hadji; Klaus Jochen Klose; Klaus-Dieter Schulz
[Validity of the breast imaging reporting and data system BI-RADS(TM) for clinical mammography in men].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 2001;173(11):1019-24.
2001: Christian Wüster; Peyman Hadji
Use of quantitative ultrasound densitometry (QUS) in male osteoporosis.
Calcified tissue international 2001;69(4):225-8.
2001: Mathias Kalder; A Milkereit; Ute-Susann Albert; Karsten Münstedt; K Goerke; Peyman Hadji; Klaus-Dieter Schulz
[Scientific presentation using modern media].
Zentralblatt für Gynäkologie 2001;123(8):450-3.
2001: Karin Bock; Volker F Duda; Peyman Hadji; Joanna Iwinska-Zelder; Annette Ramaswamy; Stephan Schmidt; Klaus-Dieter Schulz
[Sonographic variability of lactating adenoma demonstrated by a longitudinal evaluation of 4 cases].
Ultraschall in der Medizin (Stuttgart, Germany : 1980) 2001;22(4):176-81.
2000: Peyman Hadji; K Görke; Olaf Hars; T Bauer; Günter Emons; Klaus-Dieter Schulz
The influence of hormone replacement therapy (HRT) on serum leptin concentration in postmenopausal women.
Maturitas 2000;37(2):105-11.
2000: F Schütz; Christian Wüster; Peter Heilmann; Reinhard Ziegler; Peyman Hadji
No advantage of the new combined octreotide-GHRH test over established GH-stimulation tests in the diagnosis of growth hormone deficiency (GHD) in adults.
Clinical endocrinology 2000;53(6):667-74.
2000: Peyman Hadji; Olaf Hars; Karin Bock; Gerhard Sturm; T Bauer; Günter Emons; Klaus-Dieter Schulz
The influence of menopause and body mass index on serum leptin concentrations.
European journal of endocrinology / European Federation of Endocrine Societies 2000;143(1):55-60.
2000: Peyman Hadji; Olaf Hars; Gerhard Sturm; T Bauer; Günter Emons; Klaus-Dieter Schulz
The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women.
European journal of endocrinology / European Federation of Endocrine Societies 2000;142(5):445-50.
2000: Peyman Hadji; Olaf Hars; M Schüler; Karin Bock; Christian Wüster; Günter Emons; Klaus-Dieter Schulz
Assessment by quantitative ultrasonometry of the effects of hormone replacement therapy on bone mass.
American journal of obstetrics and gynecology 2000;182(3):529-34.
2000: Peyman Hadji; Olaf Hars; K Görke; Günter Emons; Klaus-Dieter Schulz
Quantitative ultrasound of the os calcis in postmenopausal women with spine and hip fracture.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2000;3(3):233-9.
2000: Ute-Susann Albert; Volker F Duda; Peyman Hadji; K Goerke; F Hild; Karin Bock; Annette Ramaswamy; Klaus-Dieter Schulz
Imprint cytology of core needle biopsy specimens of breast lesions. A rapid approach to detecting malignancies, with comparison of cytologic and histopathologic analyses of 173 cases.
Acta cytologica 2000;44(1):57-62.
1999: Peyman Hadji; Olaf Hars; K Bock; Ute-Susann Albert; M W Beckmann; Günter Emons; K Schulz
Age changes of calcaneal ultrasonometry in healthy German women.
Calcified tissue international 1999;65(2):117-20.
1999: Peyman Hadji; Olaf Hars; Christian Wüster; Karin Bock; U S Alberts; H G Bohnet; Günter Emons; Klaus-Dieter Schulz
Stiffness index identifies patients with osteoporotic fractures better than ultrasound velocity or attenuation alone.
Maturitas 1999;31(3):221-6.
1999: Christian Wüster; Peyman Hadji; G Blaul; I Nass-Griegoleit
[Quantitative bone ultrasound (QUS) of the heel bone for diagnosis of osteoporosis in the general community].
Zentralblatt für Gynäkologie 1999;121(3):137-42.